Assyro AI

Orange Book product · Brand (NDA)

DEXILANT

DEXLANSOPRAZOLE

Brand (NDA)NDA 022287TE ABRX TAKEDA PHARMS USA

At a glance

Jan 30, 2009

Approved

Brand (NDA)

Application

AB

TE code

14

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Jan 30, 2009

    17 yr 8 mo ago

  2. Patent 8461187 expires

    Listed drug product patent expiration.

    Jan 17, 2026

    5 mo ago

  3. Patent 9238029 expires

    Listed drug product patent expiration.

    Jan 17, 2026

    5 mo ago

  4. Patent 9011926 expires

    Listed drug product patent expiration.

    Feb 24, 2026

    4 mo ago

  5. Today

  6. Patent 8461187*PED expires

    Listed listed patent expiration.

    Jul 17, 2026

    in 28 d

  7. Patent 7790755 expires

    Listed drug product patent expiration.

    Aug 02, 2026

    in 1 mo

  8. Patent 8105626 expires

    Listed drug product patent expiration.

    Sep 27, 2026

    in 3 mo

  9. Patent 7790755*PED expires

    Listed listed patent expiration.

    Feb 02, 2027

    in 8 mo

  10. Patent 8105626*PED expires

    Listed listed patent expiration.

    Mar 27, 2027

    in 9 mo

  11. Patent 8871273 expires

    Listed drug product patent expiration.

    Jan 11, 2028

    in 1 yr 7 mo

  12. Patent 8173158 expires

    Listed method-of-use patent (U-951) expiration.

    Mar 17, 2030

    in 3 yr 10 mo

  13. Patent 8173158 expires

    Listed method-of-use patent (U-950) expiration.

    Mar 17, 2030

    in 3 yr 10 mo

  14. Patent 8173158 expires

    Listed method-of-use patent (U-949) expiration.

    Mar 17, 2030

    in 3 yr 10 mo

  15. Patent 8173158*PED expires

    Listed listed patent expiration.

    Sep 17, 2030

    in 4 yr 4 mo

  16. Patent 9233103 expires

    Listed method-of-use patent (U-1805) expiration.

    Mar 05, 2032

    in 5 yr 10 mo

Pharmaceutical detail

Active ingredient

DEXLANSOPRAZOLE

Strength

60MG

Dosage form

CAPSULE, DELAYED RELEASE

Route

ORAL

TE code

AB

Application

NDA 022287

Product number

002

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (14)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8461187Jan 17, 20265 mo ago
Product
9238029Jan 17, 20265 mo ago
Product
9011926Feb 24, 20264 mo ago
Product
8461187*PEDJul 17, 2026in 28 d
7790755Aug 02, 2026in 1 mo
Product
8105626Sep 27, 2026in 3 mo
Product
7790755*PEDFeb 02, 2027in 8 mo
8105626*PEDMar 27, 2027in 9 mo
8871273Jan 11, 2028in 1 yr 7 mo
Product
8173158Mar 17, 2030in 3 yr 10 mo
U-951
8173158Mar 17, 2030in 3 yr 10 mo
U-950
8173158Mar 17, 2030in 3 yr 10 mo
U-949
8173158*PEDSep 17, 2030in 4 yr 4 mo
9233103Mar 05, 2032in 5 yr 10 mo
U-1805
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.